Company Filing History:
Years Active: 2011
Title: Innovator Srinivasulu Kota and His Contributions to CNS Disorders
Introduction
Srinivasulu Kota, a prominent inventor based in Hyderabad, Telangana, India, has made significant strides in the field of medicinal chemistry. With a focus on developing new therapeutic agents, Kota's work is pivotal in addressing central nervous system (CNS) disorders, demonstrating the critical role that innovative minds play in advancing healthcare solutions.
Latest Patents
Kota holds a patent for aminoaryl sulphonamide derivatives. This invention, characterized by a specific formula, is designed for the treatment of CNS disorders related to or affected by the 5-HT receptor. The pharmacological profiles of these derivatives indicate high affinity binding with 5-HT receptors, alongside good selectivity towards the receptor. Additionally, the patent encompasses various stereoisomers, salts, methods of preparation, and medicines containing these aminoaryl sulphonamide derivatives, highlighting the comprehensive nature of his work.
Career Highlights
Srinivasulu Kota is associated with Suven Life Sciences Limited, a company known for its innovative research and development in the pharmaceutical sector. His career is marked by a dedication to improving therapeutic options and exploring new avenues for treatment in CNS-related conditions. Collaborating with a talented team, Kota's contributions have positioned him as a valuable asset in the realm of pharmaceutical innovation.
Collaborations
Kota works alongside esteemed colleagues such as Venkata Satya Nirogi Ramakrishna and Vikas Shreekrishna Shirsath, enhancing the collective expertise within their team at Suven Life Sciences Limited. These collaborations foster a dynamic environment conducive to innovative thinking and the development of groundbreaking solutions for pressing medical needs.
Conclusion
Srinivasulu Kota's commitment to innovation in the treatment of CNS disorders showcases the vital impact inventors have on healthcare advancements. His patent not only emphasizes the potential of new pharmacological compounds but also reflects the collaborative spirit within the scientific community aimed at improving patient outcomes. As he continues his work at Suven Life Sciences Limited, the future looks promising for further innovations in the field.